Use of the autologous molecularly targeted cell products for neurooncological diseases
Diseases include: relapsing glioblastoma multiforme, metastases of breast and lung cancer to the brain and spinal cord, other malignant tumors with metastases to the brain.
Therapy principle: The cell preparation of autologous peripheral blood mononuclear cells (PBMCs) is processed by perturbagens (low molecular pharmaceutical agents). The BMCP contains autologous peripheral blood mononuclear cells (PBMCs) (A component), containing 1-2% of autologous CD34+, CD45+ hematopoietic stem cells (HSCs) of general number of PBMCs, about 50% of allogenic immunocompatible mesenchymal stromal stem cells (MSSCs) with CD10+, CD13+, CD44+, CD90+ (Thy-1), CD105+, CD34-, CD45- and CD117- markers, the line of autologous or immunocompatible allogenic СD133+neural stem cells (NSCs) (B component), which have been transcriptome-modified by perturbagen (low molecular agent approved for clinical application) and leads to the development of the NSCs secretome that is able to block the intercellular integrin/focal adhesion pathway on the cancer stem cells, and an additive which is represented by the biologically stable an sterile transfusion medium with the following cell concentrations per 1 ml of the additive: A component – 0.8×106 – 4×106 cells; B component - – 4×103 – 3,3×105 cells.
The product can be used for intratissular administration in the therapy of primary and metastatic malignant tumors of the brain and spinal cord where the biodegradable polymer matrix Spherogel is used as an additive.
Result: The product can block the intracellular signal transduction pathway of the integrins and signal adhesion in the cancer stem cells and cancer cells, in primary and metastatic tumors of the brain and is able to improve the survival rates and lifespan of such cancer patients by 2 to 2.5 times.
